Cantor Fitzgerald Reaffirms Overweight Rating for Zevra Therapeutics (NASDAQ:ZVRA)
Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report)‘s stock had its “overweight” rating reissued by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports. A number of other research analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price […]
3 Oct 03:46 · The Cerbat Gem